Adverse ocular events related to belantamab mafodotin for treatment of multiple myeloma

被引：0

作者：

Lent-Schochet, Daniella ^{[1
]}

Mokhashi, Nikita ^{[1
]}

Vidyasagar, Nitin ^{[1
]}

Farooq, Asim ^{[1
]}

机构：

[1] Univ Chicago Med, Chicago, IL USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2024年 / 65卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

4100

引用

页数：2

共 50 条

[1] Belantamab mafodotin for the treatment of multiple myeloma
Wang, B.
Wu, C.
Zhong, Q.
Ling, L.
Wu, Z.
Yu, B.
Gao, X.
Zeng, H.
Yang, D-H
DRUGS OF TODAY, 2021, 57 (11) : 653 - 663
[2] Impact of baseline ocular conditions on belantamab mafodotin-related corneal events in relapsed/refractory multiple myeloma
Popat, Rakesh
Kazantzi, Aikaterini
Kleinman, David
Lichenstein, Carolyn
Paka, Prani
Salter, John
Byrne, Julie
Doherty, Allison
Esposti, Simona Degli
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 65 - 66
[3] Belantamab mafodotin in multiple myeloma
Martino, Enrica Antonia
Bruzzese, Antonella
Iaccino, Enrico
Labanca, Caterina
Mendicino, Francesco
Mimmi, Selena
Lucia, Eugenio
Olivito, Virginia
Neri, Antonino
Morabito, Fortunato
Vigna, Ernesto
Gentile, Massimo
EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (11) : 1043 - 1047
[4] Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
Sheikh, Semira
Lebel, Eyal
Trudel, Suzanne
FUTURE ONCOLOGY, 2020, 16 (34) : 2783 - 2798
[5] Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin
Menardais, B.
Soethoudt, M.
Espargilliere, D.
Mouriaux, F.
JOURNAL FRANCAIS D OPHTALMOLOGIE, 2021, 44 (05): : 766 - 768
[6] Belantamab-mafodotin treatment for relapsed or refractory multiple myeloma
Stocker, Nicolas
HEMATOLOGIE, 2020, 26 (02): : 99 - 100
[7] Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma
Abeykoon, Jithma P.
Vaxman, Luliana
Patel, Sanjay V.
Kumar, Shaji
Young, Kimberly S.
Ailawadhi, Sikander
Larsen, Jeremy T.
Gonsalves, Wilson I.
Kourelis, Taxiarchis
Leung, Nelson
Warsame, Rahma M.
Hobbs, Miriam A.
Fonder, Amie
Hwa, Yi L.
Bergsage, P. Leif
Lacy, Martha Q.
kumar, S. Vincent Raj
Gertz, Morie A.
Kapoor, Prashant
BLOOD, 2021, 138
[8] BELANTAMAB MAFODOTIN IN A PATIENT WITH REFRACTORY MULTIPLE MYELOMA
Luz Gema, Roman
Borja, Puertas
Alberto, Hernandez
Sandra, Gomez
Felipe, Pena
Danylo, Palomino
Bea, Rey
Marta, Fonseca
Raul, Azibeiro
Elena, Alejo
David, Alonso
Jose Maria, Navarro
Veronica, Gonzalez
Noemi, Puig
Maria Victoria, Mateos
HAEMATOLOGICA, 2021, 106 (10) : 334 - 334
[9] Belantamab mafodotin for relapsed or refractory multiple myeloma
David Gil-Sierra, Manuel
del Pilar Briceno-Casado, Maria
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (06) : 1375 - 1380
[10] Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Hungria, Vania
Robak, Pawel
Hus, Marek
Zherebtsova, Vera
Ward, Christopher
Ho, P. Joy
Ribas de Almeida, Ana Carolina
Hajek, Roman
Kim, Kihyun
Grosicki, Sebastian
Sia, Hanlon
Bryant, Adam
Pitombeira de Lacerda, Marcelo
Aparecida Martinez, Gracia
Sureda Balari, Anna Maria
Sandhu, Irwindeep
Cerchione, Claudio
Ganly, Peter
Dimopoulos, Meletios
Fu, Chengcheng
Garg, Mamta
Abdallah, Al-Ola
Oriol, Albert
Gatt, Moshe E.
Cavo, Michele
Rifkin, Robert
Fujisaki, Tomoaki
Mielnik, Michal
Pirooz, Nick
Mckeown, Astrid
Mcnamara, Simon
Zhou, Xiangdong
Nichols, Maureen
Lewis, Eric
Rogers, Rachel
Baig, Hena
Eccersley, Lydia
Roy-Ghanta, Sumita
Opalinska, Joanna
Mateos, Maria-Victoria
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (05): : 393 - 407

← 1 2 3 4 5 →